Abstract
A push by the drug industry to raise the price of new drugs for hypertension looks set to become the battleground for the first major fight over the free trade agreement between Australia and the United States (BMJ 2004;329: 420).
The controversial agreement, which came into force on 1 January, urges recognition of innovation and gives US drug companies new mechanisms to review the Australian government's internationally recognised system of pricing drugs on the basis of evidence of their effectiveness.
The controversial agreement, which came into force on 1 January, urges recognition of innovation and gives US drug companies new mechanisms to review the Australian government's internationally recognised system of pricing drugs on the basis of evidence of their effectiveness.
| Original language | English |
|---|---|
| Pages (from-to) | 213-213 |
| Number of pages | 1 |
| Journal | BMJ (Clinical research ed.) |
| Volume | 330 |
| Issue number | 7485 |
| DOIs | |
| Publication status | Published - 29 Jan 2005 |